SynAct Pharma AB

Stockholm Stock Exchange SYNACT.ST

SynAct Pharma AB Total Non-Current Liabilities for the year ending December 31, 2023: USD 2.65 M

SynAct Pharma AB Total Non-Current Liabilities is USD 2.65 M for the year ending December 31, 2023, a 2,514.78% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

SynAct Pharma AB Total Non-Current Liabilities for the year ending December 31, 2022 was USD 101.52 K, a -56.30% change year over year.
SynAct Pharma AB Total Non-Current Liabilities for the year ending December 31, 2021 was USD 232.31 K.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

Stockholm Stock Exchange: SYNACT.ST

SynAct Pharma AB

CEO	Mr. Jeppe Ovli Ovlesen EE, MBA
IPO Date	July 11, 2016
Location	Sweden
Headquarters	Scheelevägen 2
Employees	5
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Drugstores & Retail Pharmacies Vaccines

Description

SynAct Pharma AB, through its subsidiary, SynAct Pharma ApS, develops medicines for acute deterioration in inflammatory diseases. The company is developing AP1189, a drug candidate for the treatment of rheumatoid arthritis and idiopathic membranous glomerulonephritis. It has a partnership with the University Of Örebro to study the reduction of inflammation in vascular disease. The company was founded in 2012 and is headquartered in Lund, Sweden.

Key trends

Past 5 years